Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of TQB2825 versus immunochemotherapy in relapsed or refractory follicular lymphoma
CTR20253778Phase 3Active
- Sponsor
- China Grand Pharmaceutical and Healthcare Holdings
- Start
- Nov 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tqb2825 in follicular lymphoma (FL), sponsored by China Grand Pharmaceutical and Healthcare Holdings. Started Nov 2025; status: active.
02
Drugs
tqb2825
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20253778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253778.